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Allopregnanolone (Allo), a neurosteroid, has emerged as a promising promoter of
endogenous regeneration in brain. In a mouse model of Alzheimer’s disease, Allo induced
neurogenesis, oligodendrogenesis, white matter generation and cholesterol homeostasis
while simultaneously reducing β-amyloid and neuroinflammatory burden. Allo activates
signaling pathways and gene expression required for regeneration of neural stem cells and
their differentiation into neurons. In parallel, Allo activates systems to sustain cholesterol
homeostasis and reduce β-amyloid generation. To advance Allo into studies for chronic
human neurological conditions, we examined translational and clinical parameters: dose,
regimen, route, formulation, outcome measures, and safety regulations. A treatment
regimen of once per week at sub-sedative doses of Allo was optimal for regeneration
and reduction in Alzheimer’s pathology. This regimen had a high safety profile following
chronic exposure in aged normal and Alzheimer’s mice. Formulation of Allo for multiple
routes of administration has been developed for both preclinical and clinical testing.
Preclinical evidence for therapeutic efficacy of Allo spans multiple neurological diseases
including Alzheimer’s, Parkinson’s, multiple sclerosis, Niemann-Pick, diabetic neuropathy,
status epilepticus, and traumatic brain injury. To successfully translate Allo as a therapeutic
for multiple neurological disorders, it will be necessary to tailor dose and regimen to the
targeted therapeutic mechanisms and disease etiology. Treatment paradigms conducted
in accelerated disease models in young animals have a low probability of successful
translation to chronic diseases in adult and aged humans. Gender, genetic risks, stage
and burden of disease are critical determinants of efficacy. This review focuses on recent
advances in development of Allo for Alzheimer’s disease (AD) that have the potential to
accelerate therapeutic translation for multiple unmet neurological needs.
Keywords: allopregnanolone, Alzheimer’s disease, β-amyloid, neurogenesis, regeneration, cholesterol
homeostasis, myelin, treatment regimen
INTRODUCTION
Neurosteroids, including allopregnanolone (Allo), are a class of
neural messengers that regulate multiple processes in brain from
ion channel properties to systems regeneration. Therapeutically
it is possible to develop neurosteroid analogs to selectively tar-
get one action or to use endogenous neurosteroid molecules as
systems biology regulators. Each strategy has its strengths and
weaknesses. Depending upon the targeted disease and mechanism
therein, it is possible to selectively activate a subset of responses
or the full complement of potential responses. Therapeutic appli-
cation of neurosteroids to achieve efficacy in a disease state
requires both the understanding of the disease and the systems
pharmacology of the neurosteroid (Brinton, 2013).
This review, while largely focused on therapeutic develop-
ment of Allo for Alzheimer’s disease (AD), raises issues that
are applicable more broadly to other diseases for which Allo
may have therapeutic benefit. Thus the review is structured
around a framework of considerations that matter. To substan-
tially advance translational research that is predictive of clinical
outcome, we address multiple issues that will ultimately deter-
mine translational feasibility and success of Allo across multi-
ple disease conditions. Lastly, most neurodegenerative diseases
have no cure although in some instances palliative care extends
life but not function. Therapeutics to prevent neurodegener-
ative disease in populations at risk, delay progression of dis-
ease in those affected and restore function in those with late
stage disease remain elusive. It is our goal to enable others
in the field to advance with greater speed and greater success
by considering key aspects of translational research that really
matter.
MOLECULAR PHARMACOLOGY MATTERS
Mechanisms of drug action should be optimally identified,
confirmed and characterized in preclinical studies before
Frontiers in Cellular Neuroscience www.frontiersin.org July 2014 | Volume 8 | Article 203 | 1
Irwin et al. Endogenous regenerative therapy for Alzheimer’s disease
progressing to clinical trials (Becker et al., 2014). Metabo-
lites of progesterone with reduced A-ring steroid structures are
potent endogenous agonist modulators of gamma-aminobutyric
acid (GABA) type A receptors (GABAARs). The GABAAR
is a ligand-gated ion channel and is primarily associated
with inhibition of or fine-tuning of excitatory neurotransmis-
sion. The neurosteroid progesterone metabolites that modulate
the GABAAR include 3α-hydroxy-5β-pregnan-20-one (preg-
nanolone); 3α-hydroxy-5β-pregnan-20-one (allopregnanolone;
Allo; 3α,5β-tetrahydroprogesterone) and its 21-hydroxylated
derivative: tetrahydro-DOC (THDOC) derived from A-ring
reduction of deoxycorticosterone. Of these metabolites, Allo is
amongst the most potent endogenous allosteric modulators of
the GABAAR (Belelli and Lambert, 2005). Within the mammalian
brain, Allo has been shown to modulate anxiety, depression,
seizure activity, sedative-hypnotic activity, and the immune sys-
tem. Adding to this list, we have shown that Allo promotes the
neuroregenerative system and modifies the course of neurodegen-
erative disease.
Neurosteroid molecular structures and their structure-activity
relationship with their cognate receptors have undergone eons
of co-evolutionary selection. Steroid binding site-containing
GABAARs could have evolved during early chordate evolu-
tion, possibly between the branch points of Cephalochordata
(lancelets) and Agnatha (lampreys) (Paul and Purdy, 1992).
Much earlier, phylogenetic studies conclude that ligand gated ion
channels evolved from protoreceptors in unicellular organisms
(Pierobon et al., 2004).
Ionotropic GABAARs primarily transport chloride and bicar-
bonate ions. The potencies and efficacies of neurosteroids includ-
ing Allo depend on the subunit composition of GABAARs.
GABAergic neurotransmission can be fine-tuned by allosteric
modulation at GABAAR binding sites for barbiturates, benzo-
diazepines, anesthetic alcohols, and neurosteroids. At low con-
centrations, neurosteroids bind to GABAAR at distinct sites to
act as positive or negative modulators of GABAAR function
(Gee et al., 1987, 1988). Allo is a potent positive allosteric
activator of GABAAR channels that at nanomolar concentra-
tions enhances the apparent affinity of GABA for GABAAR and,
at micromolar concentrations, can directly activate GABAAR
chloride channels. Allo binds to two transmembrane sites of
the heteropentameric GABAAR assembled from eight subunit
families (Hosie et al., 2006). GABAAR binding sites have the
general subunit stoichiometry 2α:2β:1γ. GABAAR channel com-
plexes that occur at the synaptic cleft have a higher threshold
for activation and display phasic conductance. In contrast to
synaptic GABAARs, a subset of extrasynaptic GABAARs, con-
tain the neurosteroid-sensitive δ subunit making them phar-
macologically distinct and display a tonic conductance pattern
(Meldrum and Rogawski, 2007). GABAARs have been identi-
fied by electron microscopy in adult hippocampal subgranular
zone (SGZ) progenitor cells (Mayo et al., 2005). Surrounding
local interneurons that project towards the neurogenic niche and
release GABA to adult dentate granule cells are subjected to
tonic GABAergic signaling via δ-subunit-containing GABAARs
(Overstreet Wadiche et al., 2005). Functionally, GABA plays a key
role in the generation of spontaneous network activity within
immature dentate granule cells (Owens and Kriegstein, 2002;
Sipila et al., 2004).
GABAergic signaling likewise controls proliferation of adult
progenitor cells within the subventricular zone (SVZ) neuro-
genic niche (Liu et al., 2005). Progenitor cells in the SVZ co-
express GABAAR β2, β3 receptor subunits, GAD65/67 and GFAPδ
(Dieriks et al., 2013). The expression of GAD65/67 was detected
at lower amounts in the SVZ than in the caudate nucleus, and
co-labeling was observed with GABAAR β2, β3, and PCNA, sug-
gesting that cells with these markers utilized GABA from early
neurogenesis until maturity. GABAAR γ2 was the most abundant
and highly localized to the SVZ. GABAARs are found throughout
the SVZ on all major cell types, however GABAAR γ2 shows the
highest specific expression in the SVZ (Dieriks et al., 2013).
Through a PKC-dependent signaling mechanism, the neu-
rosteroid THDOC selectively potentiated phosphorylation and
membrane insertion of the α4/δ subunit-containing extrasynaptic
GABAAR subtypes mediate tonic conductance in the dentate
gyrus (Abramian et al., 2014). This effect of THDOC was specific
as it did not phosphorylate α5/δ or KCC2 (Abramian et al.,
2014).
The mechanism of action for Allo activated cell cycle gene
expression in neural stem cells is mediated by binding to GABAAR
to elicit an efflux of chloride and a concomitant influx of calcium
that contributes to the induction of cell signaling events which
lead to gene transcription of mitotic genes and downregulation
of anti-mitotic genes (Brinton, 2013). A rapid rise in intracellular
calcium, and subsequent activation of the cell cycle, initiates neu-
rogenesis (Wang et al., 2005; Wang and Brinton, 2008; Brinton,
2013). Upon exogenous administration, a threshold brain con-
centration of Allo in neural progenitor cells of the neurogenic
niches, activates a signaling cascade to trigger cell proliferation
(Wang et al., 2005; Wang and Brinton, 2008; Brinton, 2013).
Allo in blood and brain is subsequently enzymatically cleared
within a timeframe of minutes to hours (Zhu et al., 2001; Timby
et al., 2006; Irwin and Brinton, 2014) sufficient to allow regener-
ative system required for Allo-induced neurogenesis to continue
(Brinton, 2013).
Collectively these data provide a window into the richness of
the GABAAR system and how Allo modulates the function of
these receptors to affect both the excitability of the brain and
its regenerative capacity. The unanticipated link of the GABAAR
to the regeneration of neural stem/progenitor cells suggests the
possibility that other unanticipated and exciting relationships
have yet to be identified.
CHOLESTEROL AND THE STEROIDOGENIC SYSTEMMATTER
The brain must synthesize its own supply of cholesterol from
acetyl-CoA independent of peripherally circulating cholesterol.
Because all steroids are generated from cholesterol, changes in
cholesterol homeostasis will inevitably affect steroidogenesis.
Cholesterol must be delivered to and from cells by lipoproteins
which include low-density lipoproteins (LDL) and high-density
lipoproteins (HDL). The lipoprotein component ApoE, shuttles
cholesterol between cells through the interstitial fluid and there-
fore regulates the distribution and redistribution of cholesterol to
each cell type (Mahley, 1988). Cholesterol is transported within
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the cell via steroidogenic acute regulatory protein (StAR) to the
mitochondrial membrane translocator protein (TSPO). TSPO
is a mitochondrial rate-limiting control checkpoint regulating
cholesterol uptake and thus the synthesis of neuroactive steroids
(Rupprecht et al., 2010; Irwin and Brinton, 2014). TSPO forms a
cholesterol transport pore in the mitochondrial inner membrane
with other proteins that include the StAR, voltage-dependent
anion channel protein (VDAC), and adenine nucleotide trans-
porter protein (ANT).
The cholesterol transport pore transports cholesterol to the
mitochondrial matrix to be converted into pregnenolone by the
cytochrome P450 side-chain cleavage (CYP450scc) enzyme (Liu
et al., 2006). Pregnenolone diffuses out of the mitochondrial
compartment and is converted in the cytosol to progesterone by
3β-hydroxysteroid dehydrogenase (3β-HSD). Two enzymes, 5α-
reductase (5α-R) type-I and 5α-hydroxysteroid dehydrogenase
(3α-HSD) are required to synthesize Allo from progesterone
(Mellon et al., 2001; Mellon, 2007).
Allo is a reduced metabolite of progesterone, synthesized
in the gonads, adrenal cortex, and the central nervous system
(Genazzani et al., 2000). In the central and peripheral nervous
systems, Allo synthesis occurs primarily in glial cells—astrocytes,
oligodendrocytes, and Schwann cells and in many neuronal cell
types including neural progenitors (Melcangi et al., 1996; Griffin
and Mellon, 2001; Mellon and Vaudry, 2001; Benarroch, 2007).
An expression pattern of progesterone converting enzymes
is evident in both hippocampus and cortex. Endogenous Allo
production is controlled by the rate-limiting reduction of pro-
gesterone to 5α-dihydroprogesterone (5α-DHP) by 5α-R. Pro-
gesterone is converted to Allo by the sequential action of 5α-
R type-I, to 5α-DHP, which is then converted by 3α-HSD to
form Allo. 5α-reductase and 3α-hydroxysteroid dehydrogenase
are functionally expressed in pluripotent progenitors, neural pro-
genitor cells, and subsets of hippocampal neurons that contain
5α-R and 3α-HSD (Melcangi et al., 1996). Subsequently, 3α-HSD
catalyzes conversion of 5α-DHP into Allo. Amyloid-β-binding
alcohol dehydrogenase (ABAD) is an enzyme that is associated
with mitochondria and facilitates back conversion of Allo to 5α-
DHP (Yang et al., 2005). Interestingly, anti-depressants, such as
fluoxetine, were demonstrated to increase Allo production and
although not directly correlated, increased neurogenesis (Malberg
et al., 2000; Uzunova et al., 2004, 2006).
Increasing evidence indicates that altered cholesterol home-
ostasis is linked to neuropathologies including AD (Schumacher
et al., 2004; Mellon et al., 2008; Brinton, 2013). In addition
to the mechanism of action whereby Allo induces neurogenesis
(Brinton, 2013), Allo regulates cholesterol homeostasis via mech-
anisms that increases liver-X-receptor (LXR) and pregnane-X-
receptor (PXR; Chen et al., 2011). LXR is a nuclear hormone
receptor abundant in the brain, primarily expressed in glial
cells and acts as a molecular sensor of cholesterol levels and
initiates cholesterol clearance (Whitney et al., 2002; Jakobsson
et al., 2012). Loss of either LXRα or LXRβ subtype expression
exacerbated AD-related pathology in APP/PS1 double transgenic
mice (Zelcer et al., 2007). Loss of LXR has been shown to repress
cortical neurogenesis particularly during late-embryonic stage
development of layer II/III (Fan et al., 2008). LXR activation
increases cholesterol efflux through increased ABCA1 and ApoE
expression, and prevents overactivation of γ-secretase and over-
production of Aβ (Whitney et al., 2002; Shenoy et al., 2004;
Jiang et al., 2008). LXR activation improved cognitive function in
multiple mouse models of amyloidogenesis (Schultz et al., 2000;
Whitney et al., 2002; Yang et al., 2006; Xiong et al., 2008; Donkin
et al., 2010; Leduc et al., 2010a).
LXRs are recruited to ABCA1 gene promoter regions and
ApoE expression to decrease Aβ plaque formation and increase
Aβ clearance (Koldamova et al., 2010) through phagocytosis by
microglia (Terwel et al., 2011). Further, LXRs are recruited to
the ABCG1 promoter in a ligand-dependent manner to alter
epigenetic histone methylation allowing for a relaxed chromatin
structure accessible to further gene expression and cholesterol
efflux (Jakobsson et al., 2012). LXRs reduce neuroinflammation
by inhibition of inflammatory genes (Zelcer et al., 2007). Inflam-
matory cytokines reach high levels in AD and when suppressed by
LXR activation, enhance the phagocytic activity of microglia and
thus Aβ clearance. LXR ligands activate PXR (Riddell et al., 2007).
In parallel with an Allo-induced increase in LXR expression in
the pre-pathology condition, Allo also increased PXR expression
in the pre-pathology 3xTgAD mouse brain (Chen et al., 2011).
PXR activation, primarily in neurons, induces cytochrome P450
3A (CYP3A) enzymes including CYP3A4 and CYP3A13 and sub-
sequent cholesterol hydroxylation and activation of organic anion
transporters (OATs) for cholesterol extrusion (Sun et al., 2003).
In addition to increased LXR and PXR expression, Allo treatment
initiated in pre-Aβ pathology 3-month-old 3xTgAD mice treated
once per week for 6 months increased expression of 3-hydroxy-
3-methyl-glutaryl-CoA-reductase (HMG-CoA-R) (Chen et al.,
2011). Although HMG-CoA-R is the rate-limiting enzyme in
cholesterol synthesis, it is also required for production of oxys-
terols that activate LXR and PXR-mediated gene transcription of
cholesterol- and lipid-transport proteins (Leduc et al., 2010b).
These data predict that an Allo-induced increase in brain LXR
and PXR leads to increased cholesterol efflux, thereby reduc-
ing gamma-secretase activation by cholesterol-laden lipid rafts.
Allo-stimulated cholesterol efflux is a plausible mechanism for
the observed reduction of 27 kD and 56 kD intraneuronal Aβ
oligomers after 6 months of once per week treatment (Chen et al.,
2011).
In vivo, brain cholesterol homeostasis and intraneuronal Aβ
are tightly coupled with Allo efficacy (Chen et al., 2011). Depo-
sition of Aβ in the extracellular compartment disconnected
this coupled pathway and led to a loss of Allo efficacy in
advanced stages of AD-like pathology in the 3xTgAD model.
Allo significantly reduced Aβ generation in hippocampus, cor-
tex, and amygdala, which was paralleled by decreased mito-
chondrial ABAD and reduced microglia activation assessed as
reduced expression of Iba-1 (Chen et al., 2011). A reduction in
ABAD expression lowers mitochondrial dysfunction and simul-
taneously decreases the amount of Allo that is enzymatically
back-converted to its precursor steroid 5αDHP. Allo may stimu-
late oligodendrocyte progenitor cells in addition to neural pro-
genitor cells and since Allo is a metabolite of progesterone,
the observed increases in oligodendrogenesis with progesterone
treatment could be due to Allo (Schumacher et al., 2012). The
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myelin marker CNPase, a myelination marker, was increased
by once per week Allo, indicating myelinating capabilities in
the 3xTgAD mouse model (Chen et al., 2011). In the pre-
Aβ pathology cohort, 3-month-old 3xTgAD mice displayed
increased expression of liver-X-receptor, pregnane-X-receptor,
and 3-hydroxy-3-methyl-glutaryl-CoA-reductase (HMG-CoA-
R), three key proteins that regulate cholesterol homeostasis (Chen
et al., 2011). Collectively, Allo is a systems biology regulator
that promotes the neuroregenerative system with a simultane-
ous reduction of AD pathology in the 3xTgAD male mouse
model.
NEUROSTEROID FORMULATION MATTERS
The physico-chemical properties of Allo create a challenge for
aqueous formulation. Allo’s low molecular weight (318.49 g/mol)
and low number of hydrogen bond donors (one) and acceptors
(two) are advantageous brain-targeting properties. However, the
logP-value for Allo, 5.042, poses a solubility challenge for aqueous
formulation and thus hinders its use as an orally administered
drug (Luchetti et al., 2010). Further challenges exist for enteral
absorption of Allo after absorption. To avoid the issues with
Allo absorption through the oral route, Allo formulations were
developed for parenteral routes of administration.
The physico-chemical properties of SBECD aid in solubiliza-
tion of drug molecules with low aqueous solubility including
Allo. SBECD is a chiral molecule composed of 7 α-D glucopy-
ranose units with a molecular weight of approximately 2163
(molecular formula C42H70−nO35•(C4H8SO3Na)n•xH2O [n =
∼6.6]; Figure 1). As does its parent molecule, 2-hydroxypropyl
β-cyclodextrin (HBCD; HPBCD), sulfobutylether β-cyclodextrin
(SBECD) has a primary face diameter of 7.8 Å (or 0.78 nanome-
ters) and a secondary face diameter of 15.3 Å (or 1.53 nanome-
ters). The SBECD chemical structure differs in the side chain
hydroxyl groups of HBCD, replaced by sulfo-butyl-ethers thus
improving its solubility properties. Multiple SBECD molecules
surround each Allo molecule to enable aqueous solubility and
enhance delivery properties (Figure 1).
The pharmacokinetics of SBECD revealed a low volume of
distribution (Vd) corresponding to extracellular water and a short
elimination half-life (t1/2) (Luke et al., 2010). Renal clearance of
SBECD was at a rate corresponding to the glomerular filtration
rate in all species investigated. A single IV dose of 600 mg/kg
SBECD was administered to male mice. Clearance and Vd were
20.5 mL/min/kg and 0.98 L/kg, respectively; the t1/2 was 0.6 h
(Luke et al., 2010). In the rabbit, clearance was 5.5 mL/min/kg, Vd
was 0.24 L/kg, and t1/2 was 0.5 h. A single IV dose of 240 mg/kg
SBECD in the dog resulted in a clearance of 4.7 mL/min/kg, Vd of
0.43 L/kg, and t1/2 of 1.1 h (Luke et al., 2010). No clinical evidence
of toxicity was found in dogs at daily doses up to 1500 mg/kg
(Luke et al., 2010). The no observed adverse event level (NOAEL)
for IV SBECD, associated with vacuole uptake of renal proximal
tubule epithelium, was set at 80 and 30 mg/kg in rats and dogs,
following bolus injection. The NOAEL associated with foamy or
lipid-laden macrophages in the lung was established at 160 mg/kg
in rats and 200 mg/kg in dogs. SBECD is renally excreted intact
and in all studies, no evidence of metabolism of SBECD exists
(Luke et al., 2010).
FIGURE 1 | Molecular structure and formulation of allopregnanolone.
(A) Chemical structure of allopregnanolone; molecular weight 318.49 g/mol.
(B) Chemical structure of β-cyclodextrin derivatives, where R is hydrogen or
2-hydroxypropyl (CH2CHOHCH3) for HBCD or sulfobutylether ((CH2)4 SO3
Na) for SBECD. HBCD has an average molecular weight ∼1460 g/mol, with
0.7–3.15 average degrees of substitution for hydrogen. SBECD molecular
weight ∼2163 g/mol with average degrees of substitution estimated
(Continued )
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FIGURE 1 | Continued
between 6.3–6.6. (C) The β-cyclodextrins form three-dimensional cyclic
oligosaccharide toroidal structures comprised of 1,4-linked glucopyranose
molecules with a hydrophilic outer surface and a hydrophobic inner surface.
(D) Allopregnanolone in β-cyclodextrin formulation to render
allopregnanolone water soluble for rapid release in vivo. Two or more
molecules of β-cyclodextrin, represented as toroid-shaped hydrophilic caps,
form an inclusion complex with each relatively insoluble Allo molecule.
SBECD is approved for use in marketed drug products includ-
ing intravenous voriconazole, amiodarone, ziprasidone, aripipra-
zole, and maropitant (Luke et al., 2010). Human exposure data
based on Pfizer’s regulatory submission were derived from four
clinical studies where IV SBECD was administered (Luke et al.,
2010). A total of 49 healthy male volunteers received IV infusions
of SBECD alone. SBECD doses between 25 and 200 mg/kg/day
were used to assess the safety and pharmacokinetics. In patients
with renal problems, steady-state conditions indicated that even
with daily hemodialysis, SBECD was effectively eliminated during
6 h of renal replacement therapy (Hafner et al., 2010). In older
patients such as those in AD clinical trials, renal function is
an important consideration when selecting a formulation and
monitoring its safety and clearance. SBECD is relatively safe and
with intermittent exposure is unlikely to accumulate based on
human pharmacokinetic studies.
The therapeutic dose of Allo for humans is likely within the
dose-range explored in previous clinical studies with IV Allo 0.05–
0.9 mg/kg (Timby et al., 2006; van Broekhoven et al., 2007; Grant
et al., 2008; Kask et al., 2008, 2009). With a 30% SBECD formu-
lation of Allo for example, the amount of SBECD would be less
than the NOAEL with species allometric scaling. Hypothetically,
IV Allo at 0.9 mg/kg or 6.3 mg/70 kg human, in a 5 mg/ml soluble
formulation of 30% SBECD, would amount to 378 mg of SBECD
or 5.4 mg/kg. Citing the NOAEL of 160 mg/kg in rats (Luke
et al., 2010), allometric scaling to humans would approximate to
27 mg/kg, whereas the dose in this hypothetical tolerable dose
situation would be approximately 5.4 mg/kg SBECD to deliver
0.9 mg/kg Allo.
The complexation ratio of the combination of the excipient
(SBECD) and the neurosteroid (Allo) has limitations based on
solubility properties (Figure 1). The complexation ratio of Allo
with cyclodextrins such as SBECD is a major determinant of
release of Allo into the blood and brain (Figure 2). To develop
formulations with clinical utility, we tested multiple Allo/SBECD
complexation ratios on behavior in adult rats (Irwin et al., 2013).
The optimal Allo:SBECD formulation (molar ratio of 5.89) was
fully soluble and bioavailable as indicated by rapidly induced and
prolonged sedation at the maximally tolerated dose for sedation
8 mg/kg subcutaneous in rats. When the ratio was increased
(molar ratio of 23.56), the rate of Allo release into the brain was
reduced as indicated by a lack of sedation (Figure 2B). Likewise,
when the ratio was decreased (molar ratio of 1.47) relative to
optimal, the rate of Allo release into the brain was also reduced
(Figure 2B). The volume of soluble Allo administered in the sat-
urated suspension formulation is limited when dosing 8 mg/kg to
rats and results in mild sedative effects likely due to the relatively
small fully soluble fraction giving the suspension formulation
dual properties. Based on these data, it was postulated that a small
but fully soluble fraction was rapidly delivered to the brain at a low
dose followed by a slowly absorbed suspension fraction that does
not possess the release rate required for sedation at the 8 mg/kg
dose level (Irwin et al., 2013).
Efforts to synthesize water-soluble analogs of neurosteroids,
including Allo and progesterone have been made with the goal to
maintain structure-activity relationships (MacNevin et al., 2009).
Excipients with prior regulatory approval are most desirable
for formulations since they have undergone extensive toxicology
testing and are more likely to gain regulatory acceptance when
formulated with new active ingredients required to undergo their
own extensive quality and safety assessments.
FIGURE 2 | Formulation of allopregnanolone matters. (A) Percent
solubility of allopregnanolone (Allo) in 24% w/v SBECD. Allo reached an
optimal formulation of 6:1 at Allo 6 mg/ml in 24% SBECD. Solubility began
to decline, observed by precipitation, when Allo concentration was
between 8–10 mg/ml coinciding with a molar ratio of between 4–5 SBECD
molecules per Allo molecule in water at room temperature without pH
adjustment. (B) Motor control/sedation at 25 min after subcutaneous Allo
8 mg/kg to male rats measured by balance beam task on a five point scale
where 4 = reaches platform; 3 = takes steps; 2 = all paws on top; 1 = clasp;
0 = fall off beam (Irwin et al., 2013). Molar ratio was plotted to illustrate
relationship between Allo-induced loss of motor control and SBECD:Allo
complexation ratio. Via subcutaneous injection, soluble formulations with
SBECD:Allo between 7:1 and 3:1 maximally delivered Allo to systemic
circulation resulting in rapid brain uptake observed by altered motor control.
The cyclodextrin vehicle SBECD does not cross the blood brain barrier but
facilitates Allo release to steroid carrier proteins in blood. The motor
control/sedation test was used as a safety biomarker of maximally tolerable
Allo target engagement in brain.
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DOSE AND ROUTE OF ADMINISTRATION MATTER
For therapeutic use of Allo, it is imperative to determine the
optimal dose, formulation, and dosing regimen (Brinton, 2013).
The dose of Allo matters within the context of the targeted
biological system. Safety and efficacy must be balanced to avoid
unnecessary overexposure and remain consistent with a balanced
neuroendocrine system (Figure 3). For most efficacy outcomes,
Allo, like other neurosteroids, has an inverted U-shaped dose
response profile—too high or too low of an Allo dose leads to
suboptimal responses (Wang et al., 2005). Allo induces neuro-
genesis through potentiation of GABAAR chloride channels in
neural progenitor cells in a dose-dependent manner: 10, 100,
and 250 nM doses were efficacious whereas neurogenic efficacy
diminished at higher doses (Wang et al., 2005; Wang and Brinton,
2008).
In vivo, we have shown that both dose and route matter to
determine the therapeutic range and tolerability of Allo (Irwin
et al., 2011; Irwin and Brinton, 2014). In our previous in vivo
studies, subcutaneous Allo was administered in the range of 1–
20 mg/kg to mice (Wang et al., 2010). The dose of Allo 10 mg/kg
via subcutaneous route was selected for subsequent studies based
on hippocampal BrdU incorporation as an indicator of neuroge-
nesis (Wang et al., 2010). Subcutaneous Allo injections were also
shown to be effective in a mouse model of Niemann-Pick Type
C (NPC; Griffin et al., 2004) and in addition to increased myelin
formation and decreased demyelination, the efficacy of Allo was
partly due to a reduction of oxidative stress (Zampieri et al., 2009).
For human translation, subcutaneous or intramuscular injec-
tions are advantageous due to ease of administration, patient
compliance, and tolerability. Allo pharmacokinetics and phar-
macodynamics were determined by a combination of brain and
blood levels associated with degree of sedation and amount of
hippocampal neurogenesis (Irwin et al., 2013). Our recent studies
found that sedation following subcutaneously administered Allo
in the rat was more variable than the intramuscularly adminis-
tered response (Irwin et al., 2013). Our analyses indicated that
an intramuscular dose was approximately twice as potent at
inducing sedation as subcutaneous delivered in a rapid release
formulation (Irwin et al., 2013). The no-observable-adverse-
effect or subsedative dose level was finely tuned by conducting a
series of rat sedation studies within the dose range of our mouse
efficacy studies. Subsedative doses were determined to optimally
increase markers of neurogenesis including significant increases
in BrdU labeled nuclei in the hippocampus (Irwin et al., 2013).
Pharmacokinetic studies often begin with the intravenous route
to provide maximal bioavailability and inform further studies by
alternative routes. An intravenous Allo no-observable-adverse-
effect dose of 0.5 mg/kg in mice or 0.2 mg/kg to rats is predicted
by allometric species conversion calculations to be equivalent to a
human intravenous dose of approximately 0.42 mg/kg or ∼3 mg
for a 70 kg adult. Allo has been tested in preclinical models via
multiple routes of administration to establish safe dosage ranges
for each route.
When selecting an Allo dose or reviewing the available litera-
ture (Irwin et al., 2011; Irwin and Brinton, 2014), it is important
to compare and contrast the treatment methods and animal mod-
els within each study. Evaluation of therapeutic potential requires
a deep understanding of the dose and route of administration that
will influence pharmacokinetic and pharmacodynamic outcomes.
TREATMENT REGIMEN MATTERS
ALZHEIMER’S DISEASE
Neurogenesis occurs over the course of hours in the case of tran-
sitioning through the cell cycle, to months in the case of full inte-
gration into hippocampal circuitry and networks (Brinton, 2013).
Activating both regenerative and repair systems to maximize
therapeutic benefit in the ageing or degenerating brain requires
dual assessment of pathology and proliferation simultaneously.
FIGURE 3 | Sedation as a biomarker of neurosteroid target
engagement. The sedative component of GABAA receptor activation in
the brain can be used a biomarker outcome of Allo delivery and
tolerability. Through activation of the regenerative system in
intermittent pulses, Allo is beneficial for many neurological disorders. In
status epilepticus and traumatic brain injury it is important to deliver
sedative doses of continuous Allo to protect the brain from further
excitotoxicity.
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Further, multiple dosing regimens should be tested in order to
conclude that regimen does matter and to determine an optimal
therapeutic regimen. Our studies followed this plan to determine
that Allo treatment regimen matters, testing administration of
Allo every day, every other day, every week, and every month.
Results of these studies indicate that a once per week treatment
regimen with a single dose of Allo (10 mg/kg) was optimal to
promote neurogenesis while also activating systems that reduced
Alzheimer disease pathology (Chen et al., 2011).
We previously demonstrated that Allo induces neural stem cell
cycle gene expression (Wang et al., 2005) and induces key regu-
lators of cholesterol homeostasis (Chen et al., 2011) to provide
mechanistic plausibility for its therapeutic efficacy to promote
neurogenesis and cognitive function while reducing AD pathol-
ogy following intermittent dosing. Allo promotes neurogenesis
(Wang et al., 2005, 2010), recovery of learning and memory
function (Wang et al., 2010; Singh et al., 2012), and reduction of
AD pathology burden (Chen et al., 2011) in the 3xTgAD mouse
model. We have demonstrated that regeneration is achieved with
either once per month or once per week regimen of Allo (Chen
et al., 2011). In the same mouse model, the reduction of AD
pathology was achieved with once per week or every other day
regimens (Chen et al., 2011; Irwin et al., 2011; Brinton, 2013).
A combination of regeneration and reduction of pathology was
achievable with an intermittent, once per week, Allo treatment
regimen (Figure 3).
Intermittent Allo treatment regimens have shown benefit in a
spectrum of preclinical neurodegenerative disease models includ-
ing NPC (Griffin et al., 2004), diabetic neuropathy (Leonelli
et al., 2007), peripheral nerve injury (Meyer et al., 2008), mul-
tiple sclerosis (Noorbakhsh et al., 2011), and Parkinson’s disease
(Adeosun et al., 2012). Frequent or constant exposure to Allo is
not better for regenerative processes although more often than
once per week improved reduction of β-amyloid-burden disease-
modifying effects (Chen et al., 2011). By contrast, a constant
infusion treatment regimen over the course of months was anti-
regenerative and resulted in adverse outcomes (Bengtsson et al.,
2012, 2013; Irwin and Brinton, 2014). Unnecessary constant
infusion of Allo is not biologically relevant and therefore should
not be a therapeutic option for neurological disorders other than
epileptic seizure and traumatic injury (Figure 3).
Allo concentrations in blood and brain are stress respon-
sive and serve to restore normal GABAergic and hypothalamic-
pituitary-adrenal (HPA) function following stress (Crowley and
Girdler, 2014). An elevation of neurosteroids in response to
stress is an adaptive anxiolytic response in acute stress situa-
tions. However, during chronic stress and depression, a condition
collectively termed as allostatic load, system-wide decreases in
brain and plasma neurosteroid concentrations occur and overall
the response to acute stressors becomes dysfunctional (Genazzani
et al., 1998; Bernardi et al., 2000; Dong et al., 2001; di Michele
et al., 2003). Thus, a disruption in the biologic stress response
system can exacerbate stress response disorders (Crowley and
Girdler, 2014). Like the regenerative system, the stress response
system requires a recovery period. Because of the temporal con-
straints of the regenerative system in brain, other regenerative
factors are likely to have greater efficacy when administered with
intermittent treatment regimens. In contrast, those emergency
neurological conditions including traumatic brain injury and
status epilepticus (Rogawski et al., 2013; Zolkowska et al., 2013)
with intense seizure susceptibility and immediate risk of massive
glutamate excitotoxicity and hypoxia require constant infusion
regimens to dampen neuroexcitation to protect the central ner-
vous system. We postulate that during the early stages of AD
pathology development, administering pulsatile doses of Allo
is therapeutically relevant to biological systems including the
stress response system and the neuroregenerative system. Safe and
tolerable Allo dose exposure serves as a neuroendocrine signal to
initiate neuroregeneration.
Based on the therapeutic efficacy of Allo in a preclinical
AD mouse model and in normal aged mice, we predict that
Allo has potential therapeutic benefit in humans to delay pro-
gression in persons with familial early-onset AD and to pre-
vent and delay disease in late onset AD. In these populations,
Allo could be an effective therapy to promote the regenerative
potential and myelination capacity of the brain to prevent or
delay progression of mild cognitive impairment to clinically
diagnosed AD. In summary, targeting a unique mechanism of
action, Allo promotes the innate regenerative capability of the
brain by increasing the number and survival of newly generated
neurons. However, for therapeutic efficacy of Allo, it is imperative
to determine the appropriate dosing regimen specific to each
indication.
SAFETY AND TOLERABILITY MATTER
Earlier we reviewed the existing preclinical and clinical safety data
in support of Allo therapeutic development (Irwin et al., 2011;
Irwin and Brinton, 2014). Allo is a blood brain barrier penetrant
molecule with previous safety data in humans (Timby et al., 2006;
van Broekhoven et al., 2007; Grant et al., 2008; Kask et al., 2008,
2009). A cumulative dose of 0.9 mg/kg or approximately 6 mg for
a 70 kg human, was administered to 9 men and 9 women with
mean ages of 24.6 and 21.8 years respectively. Allo was generally
well-tolerated with peak blood levels of 100 nM for women and
150 nM for men (van Broekhoven et al., 2007). Self-reported seda-
tion and drowsiness were followed by and recovery followed the
metabolic half-life of circulating Allo which was eliminated within
hours (van Broekhoven et al., 2007). Physiological exposure to
Allo is highest in the third trimester of pregnancy when levels
reach 50 ng/ml or 157 nM (Luisi et al., 2000).
In human Phase 1 studies for AD, fully bioavailable intra-
venous injection of Allo in a dose escalation design will reach
a limit with mild sedation to establish the maximally toler-
ated dose following intravenous administration. Currently, the
upper physiological Allo blood concentration during the third
trimester of pregnancy sets the safe exposure boundary until
chronic toxicology studies conducted under Good Laboratory
Practice (GLP) standards in rodent and non-rodent species are
completed. Regulatory agencies require extensive and pivotal
toxicology studies prior to large clinical trials and Allo drug
product approval. These studies are necessary to demonstrate
the safety within a specified dosage range and duration of
exposure. GLP is a standardized quality system of management
controls to ensure that in non-clinical laboratory studies the
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integrity of drug products such as Allo are planned, performed,
monitored, recorded, reported and archived in a uniform, consis-
tent, reliable, reproducible manner. GLP studies include extensive
non-clinical safety tests that include specification of physico-
chemical properties generated under Good Manufacturing Prac-
tices (cGMP) and acute dose-range finding studies to chronic
toxicity tests in rodents and non-rodent species to meet or
exceed the duration of the clinical trial (Steinmetz and Spack,
2009).
In the US, all preclinical safety studies that contain investi-
gational active pharmaceutical ingredients should seek regula-
tory guidance and oversight by the FDA. Regulatory agencies
of many countries follow the International Conference on Har-
monization guidelines. Pre-meeting with the regulatory agency
will greatly improve important communication and a focused
track to develop the Investigational New Drug (IND) application.
IND approval in the US, or its equivalent application review
process in other countries, must be obtained prior to initiation of
standard clinical trials to establish safety and tolerability (Phase
I) and efficacy (Phase II). Application for compassionate use
IND requirements may be abbreviated for certain life threatening
disease conditions outside of clinical trials that require emergency
care decisions for expanded use discussed between physicians and
regulatory agencies.
Safety reporting rules and timelines must also be maintained
and monitored throughout the trial. In cases where existing
preclinical toxicology and human exposure data are available, or
highest physiological exposure has been studied, as is the case
with Allo (Luisi et al., 2000), regulatory agencies may consider
the active pharmaceutical ingredient to be sufficiently safe at a
specified dosage range to move forward with safety and efficacy
studies in humans. The entire process of drug development
including time investment and funding must be kept in mind
when planning viable therapeutic strategies for Allo. Along the
Allo drug development timeline, leverage points are gained such
as completion of chronic toxicology studies and should be shared
when permissible to accelerate expanded access for neurological
diseases similar dose, route, and treatment regimens overlap.
Toxicology studies define the safe exposure limits in animals
and the outcomes are then extrapolated to predict maximally safe
and tolerable exposure limits for initial human trials. Disease-
modifying claims are stringently reviewed and may require addi-
tional safety studies beyond the standard toxicology battery.
For example, recent AD beta-amyloid modifying therapies have
shown in clinical studies to increase the risk for vascular edema,
detected by magnetic resonance imaging (Salloway et al., 2009;
Sperling et al., 2011b, 2012). Increased risk for microbleeds
prompted regulatory agencies to require new safety measures
for candidate AD drugs in pre-clinical stages. Drug candidates
that claim to modify amyloidogenic mechanisms may require
additional preclinical assessment of the associated risk for cerebral
microhemorrhages in an appropriate animal model. Currently
several AD mouse models are considered appropriate however
these studies are costly in terms of time and money. Micro-
hemorrhage risk assessment studies require cohorts of ∼2 year
old transgenic AD mice (Pfeifer et al., 2002; Racke et al., 2005;
Demattos et al., 2012).
At the stage of dose range finding in rodents and non-
rodents, tolerability predictions can be made ranging from the
no-observed-adverse-effect level up to the maximally tolerated
dose. For neurological disorders, a well-known biomarker of Allo
target engagement and tolerability is sedation (Damianisch et al.,
2001). Inhibition of the tuberomammillary nucleus has a key
role in the sedative or sleep-inducing response to anesthetics
that act on the GABAAR (Nelson et al., 2002). The sedation
response to Allo can be objectively measured by detection of
saccadic eye movement or brain activity via electroencephalo-
gram (Figure 3; van Broekhoven et al., 2007) as was done
with benzodiazepine drug development (Van Steveninck et al.,
1993). Sedation level due to neurosteroids can also be subjec-
tively determined by clinical observation and by visual analog
scales (van Broekhoven et al., 2007). Typically, a combination
of objective and subjective measures of sedation are used to
assess tolerability. Allo induces dose-related sleep changes includ-
ing a reduced sleep onset latency and increased pre-rapid-eye-
movement sleep (Lancel, 1999). Allo has a safer tolerance profile
than most GABAAR agonists including benzodiazepine hypnotics
(Damianisch et al., 2001).
A neural network comprised of at least three discrete brain
regions promotes sedation non-rapid eye movement sleep.
GABAergic neurons of which Allo targets are in the ventrolateral
preoptic nucleus are under tonic inhibition from noradrenergic
neurons of the locus coeruleus. Inhibition of locus coeruleus
neurons results in activation of the ventrolateral preoptic nucleus
to induce sedation. GABAergic ventrolateral preoptic nucleus
neurons of which Allo acts, innervate the ipsilateral tuberomam-
millary nucleus, a posterior hypothalamic cell group important
in promoting arousal. The tuberomammillary nucleus, located
on the ventrolateral edge of the posterior hypothalamus, contains
neurons that co-express histamine and the inhibitory neurotrans-
mitter GABA, and which project to the cerebral cortex, thalamus,
and basal forebrain (Haas and Panula, 2003). These arousal-
promoting, histaminergic tuberomammillary nucleus neurons
are wake-active and are inhibited by the release of GABA and
galanin by ventrolateral preoptic nucleus neurons. In short, the
activated ventrolateral preoptic nucleus releases GABA to the
GABAAR-containing sites of the tuberomammillary nucleus thus
inhibiting release of arousal-promoting histamine into the cortex
and forebrain to induce sedation. Through a wake-sleep neu-
ronal network, at suprathreshold doses Allo allosterically poten-
tiates GABA’s apparent affinity for the GABAAR to increase the
chloride current of histaminergic neurons of the tuberomam-
millary nucleus causes sedation. The sedative response is not
the primary regenerative target and sedation is less tolerable
for treatment of chronic disease. A subsedative dose of Allo
that retains activity at Allo-sensitive neural progenitor cells is
optimal for regenerative responses and therapeutic development
(Figure 3).
In a human clinical trial, a sedation-inducing dose of Allo
briefly impaired episodic memory 10 min after the end of Allo
intravenous infusion when peak blood levels were highest (Kask
et al., 2008). Not surprisingly, a GABAAR allosteric agonist
induced temporary memory impairment in a way similar to
benzodiazepines. Chronic treatment paradigms that mimic stress
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conditions have also been shown to inhibit memory (Turkmen
et al., 2006). Allo administered twice daily at high doses to male
rats for several consecutive days decreased performance on the
Morris water maze, escape latency, path length and thigmotaxis
(Turkmen et al., 2006).
Collectively, the data indicate that the sedative properties of
Allo are dose dependent and duration of exposure dependent.
Allo administered by multiple routes of administration exhibits
an acceptable margin of safety.
REGENERATIVE POTENTIAL OF THE HUMAN BRAIN
MATTERS
Most studies in AD mouse models, have reported decreased
neurogenesis primarily in the hippocampal SGZ of the dentate
gyrus and the SVZ lateral ventricles with association with corti-
cal regions including the rostral migratory stream (Lazarov and
Marr, 2010). There is strong evidence in AD animal models
including the 3xTgAD mouse that demonstrate reduced neuro-
genesis with degree of AD pathology (Wang et al., 2007, 2010;
Rodriguez et al., 2008, 2009; Chen et al., 2011; Singh et al., 2012).
Unexpectedly, in post-mortem brain sections from AD victims,
doublecortin, a microtubule-associated protein expressed by neu-
ronal precursors and immature neurons, was increased relative
to control brain sections (Jin et al., 2004). Neural progenitors
have been isolated in vitro from post-mortem 11-week post-natal
and adult human brain demonstrating that neural progenitors are
present throughout life (Palmer et al., 2001). Further studies are
required to determine whether the doublecortin immunostaining
findings were reproducible with other antibodies or preferably
with BrdU or 14C labels. It has been demonstrated that in humans
without known neurological disorders, hippocampal neuroge-
nesis occurs throughout adulthood and tapers modestly with
advanced age (Spalding et al., 2013).
Humans exhibit substantial hippocampal neurogenesis within
the SGZ (Spalding et al., 2013) and striatal neurogenesis associ-
ated with the SVZ lateral ventricles (Ernst et al., 2014). Humans,
rather uniquely for mammals, do not demonstrate olfactory bulb
neurogenesis, as the neuroblasts originating in the neurogenic
niche of the lateral ventricle wall do not migrate to the olfactory
bulb. Carbon-dated DNA within adult hippocampal neurons
revealed that a substantial fraction of neurons were born during
adulthood (Spalding et al., 2013; Ernst et al., 2014). Each year
approximately 1.75% of the neurons turned over within the self-
renewing fraction with only a modest decline during aging. A
best-fit scenario model predicted that approximately 35% of the
hippocampal cells were cycling corresponding to slightly less than
the proportion that constitute the entire dentate gyrus region.
From these studies it was estimated that the hippocampal dentate
gyrus of human brain produces around 700 new neurons per
day. Enough neurons could be replaced in the hippocampus to
theoretically regenerate the entire hippocampal neurogenic region
over the lifespan suggesting the importance of neurogenesis.
Compared to rodents, humans may rely on neurogenesis even
more during the aging process (Spalding et al., 2013). In healthy
aging, the decline of hippocampal neurogenesis is less than the
rate of decline when adjusted for lifespan and compared with
rodent models.
Following results demonstrating hippocampal neurogenesis
throughout the lifespan, Frisen and colleagues utilized the same
14C dating method to reveal abundant neuroblasts in the human
striatum adjacent to the lateral ventricle wall and revealed a
constant turnover/generation of striatal interneurons with and
annual turnover rate of 2.7% within the renewing fraction (Ernst
et al., 2014). This recent finding highlighted a major difference
between human neurogenic niches vs. animal models. Rodents
for example have well developed rostral migratory streams that
send newborn SVZ neurons towards the olfactory bulb. Human
brains were found to shunt the equivalent neurogenic niche cells
to the striatum. In the brains of Huntington’s disease patients, a
disease related to the degeneration of striatal neurons (Zuccato
et al., 2010; Walker et al., 2011), the patient cohort in the advanced
state of the disease lacked these post-natally generated neurons
(Ernst et al., 2014).
Once new neurons develop, the cells require approximately
2 months to mature both morphologically and physiologically,
suggesting to us that an intermittent treatment regimen (Figure 3)
would be required to stimulate regeneration in this neurological
disorder. The timing of therapeutic intervention must accommo-
date the development period from which newborn cells acquire
GABAergic and glutamatergic inputs and receptors. During this
development period the young neurons are highly excitable with
increased synaptic dynamics compared to mature neurons (Gage
and Temple, 2013). This time course of regeneration, migra-
tion, differentiation, creates a temporal map that is coincident
with Allo-induced proliferation, increased learning capacity and
increased memory function (Brinton, 2013).
GENDER MATTERS
Neurological diseases that have varying prevalence, progression
and severity between men and women include AD, Parkinson’s
disease, attention deficit/hyperactivity disorders, and schizophre-
nia (Gillies and Mcarthur, 2010). Sex differences have been noted
in human safety studies of Allo, where the same intravenous dose
in men and women resulted in maximum blood levels that were
higher in men 150 nmol/L vs. 100 nmol/L in women, although
volume of distribution, elimination half-life, and the area under
the curve (AUC) adjusted for body weight did not differ (van
Broekhoven et al., 2007).
Clinical differences between females and males may result
from differences in brain morphology, neurochemistry, and func-
tional outcomes. It is hypothesized that there is a critical hormone
treatment window in the post-menopausal brain. The importance
of regimen is again demonstrated when it was shown that contin-
uous vs. cyclic progesterone administration resulted in disparate
gene expression profiles in the brain (Zhao et al., 2012). Changes
in neural gene expression profiles after alternative progesterone
therapies highlights the importance of mimicking physiologi-
cal profiles of neurosteroid exposure in order to maintain and
improve neurological health and function (Zhao et al., 2012).
Changes in pathophysiology due to gender may be important in
evaluating both efficacy and side-effect profiles during therapeu-
tic development (Figure 4). Early in 2014, a drug response gender
difference prompted the FDA to issue a safety announcement
and reduce by half the zolpidem (Ambien) dosage for women
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FIGURE 4 | Design of clinical trials for allopregnanolone should
consider both static variables and moving targets to treat neurological
disorders. Gender and genetics are static variables that influence disease
and response to treatment. Static variables impact the moving targets such
as age, hormone status, metabolism, health, and disease progression.
Successful clinical therapeutic strategies should be tailored for each disease
state and should be monitored as the disease and treatment progresses.
Dynamic biological processes require an understanding of disease system
pathogenesis to select and modify the appropriate treatment regimen.
compared to men.1 As a result, zolpidem is now the only prescrip-
tion drug with a different dose for men and women. Zolpidem,
like Allo, is a GABAA agonist with sedative hypnotic actions in
the wake-sleep neurocircuitry. Women metabolize and eliminate
zolpidem slower than men, making them more susceptible to next
morning impairment side effects.
Preclinically, a difference between sexes in Allo response was
observed in our studies whereby male rats administered bolus
injections of Allo had increased sensitivity to Allo’s sedative
effects, with greater time and levels of sedation compared to age-
matched female rats (Irwin et al., 2013). Allo may exert its effects
on males and females differently, i.e., other than through binding
postsynaptic GABAARs. The female brain may have a greater
sensitivity to Allo’s potentiation of GABA neurotransmission. In
a global ischemia mouse model, females were neuroprotected at a
dose of Allo four times lower than the required dose to protect
males (Kelley et al., 2011). These data are surprising in light
of evidence indicating that male brains have a greater number
of GABAAR binding sites relative to female brains (Juptner and
Hiemke, 1990).
1http://www.fda.gov/drugs/drugsafety/ucm334033.htm
Cyclical changes of steroids during the estrous cycle can lead
to changes in GABAARs and during late diestrus new receptors
have α4, β1 and δ GABAA receptor subunit expression (Lovick,
2008). As β1 subunit containing receptors are extrasynaptic and
carry tonic currents, upregulation should lead to a decrease in
GABAergic inhibition (Lovick, 2008). Studies in male rats have
shown that alterations in Allo plasma levels can, within min-
utes, modulate the amount of GABAergic inhibition in the peri-
aqueductal gray matter. Function changes resulting from altered
intrinsic excitability levels may affect therapeutic responsiveness
(Lovick, 2008).
Overall, there is a recognized need for a better understanding
of sex differences related to neurotherapeutic response and the
clinical relevance of such differences to inform and improve drug
development.
DISEASE TARGET AND THERAPEUTIC GOALS MATTER
ALZHEIMER’S DISEASE
Disease target
Regenerative system of the brain, cognition neural circuitry, and
etiology of pathology.
Therapeutic response to Allo
Increased hippocampal neurogenesis, increase neural progenitor
cell survival, and reverse learning and memory deficits, decreased
microglial activation, and decreased amyloid-beta pathology
(Brinton, 1994, 2013; Wang et al., 2010; Irwin et al., 2011; Singh
et al., 2012; Lo et al., 2014).
Targeted mechanism of action
Potentiation of GABA at GABAAR to depolarize neural stem cells;
regulation of LXR and PXR in cholesterol homeostasis.
Dose and treatment regimen
Intermittent exposure in mice: 10 mg/kg once weekly for 6
months (Chen et al., 2011); 1 mg/kg SC single dose, 10 mg/kg SC
single dose, 20 mg/kg single dose (Wang et al., 2010); 10 mg/kg
SC 3 times per week, for 3 months (Chen et al., 2011); 10 mg/kg
once per month, single dose (Singh et al., 2012).
Allo and other trophic factors are decreased in blood and brain
of AD patients compared to age-matched controls (Weill-Engerer
et al., 2002; Marx et al., 2006; Naylor et al., 2010). Early AD is
characterized by loss of episodic and semantic memory (Perry
et al., 2000) and signifies hippocampal dysfunction. Diagnos-
tic imaging studies using volumetric MRI revealed a decreased
hippocampal volume due to neurodegeneration of gray matter
in people diagnosed with amnestic mild cognitive impairment
that will progress to AD (Whitwell et al., 2007). In AD, restora-
tion of the dysfunctional neurogenic niche with intermittent
pulses of Allo may regain neurological order while avoiding
overstimulation.
We previously demonstrated a correlation between Allo-
induced neural progenitor cell survival and improved memory
function in the triple transgenic mouse model of AD (Brinton,
1994, 2013; Wang et al., 2010; Irwin et al., 2011; Singh et al.,
2012). Consistent with the human AD brain neurosteroid profile
(Weill-Engerer et al., 2002; Marx et al., 2006; Naylor et al.,
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2010), basal concentration of Allo in blood plasma of wild-type
mice of was significantly lower than in cortex indicating higher
brain accumulation of Allo. Higher level of brain Allo could be
attributed to locally synthesized Allo in specific brain regions
required for synaptic function. We also found that 3xTgAD mice
had lower basal levels of Allo in the cerebral cortex (3xTgAD,
6.49 ± 2.02 ng/g vs. nonTg, 10.36 ± 1.43 ng/g), suggesting
that there was either impairment of upstream Allo enzymatic
production or accelerated Allo metabolism in 3xTgAD mice brain
(Wang et al., 2010).
Within the SGZ and SVZ in male and female 3xTgAD mice
a decline in neurogenesis is correlated with age-related AD-like
pathology progression (Brinton and Wang, 2006; Rodriguez et al.,
2008, 2009; Wang et al., 2010). Our studies have demonstrated
that Allo promoted neurogenesis in the hippocampal SGZ to
reverse learning and memory deficits (Wang et al., 2010). A study
conducted in 3xTgAD mice subjected to an associative learning
and memory task were analyzed and found increased neural
progenitor cell survival of an intermittent treatment regimen with
subcutaneous Allo 10 mg/kg, 3 weeks after a single Allo treatment
and post-behavioral analyses. After 3 weeks, Allo-treatment vs.
vehicle control demonstrated that surviving BrdU-labeled cells
were located deep within the granular cell layer, consistent with
the migration pattern of newly formed cells from the SGZ to
the granule cell layer (Wang et al., 2010). In an in vivo dose-
response study, 10mg/kg SC Allo exerted the greatest neurogenic
efficacy and was the dose chosen for chronic preclinical efficacy
assessment (Wang et al., 2010).
To further assess the preclinical efficacy of Allo for AD, our
group has conducted studies of long-term intermittent exposure
to Allo. These studies with Allo were also initiated with 3-months
of age mice, prior to overt intraneuronal Aβ. In addition to
neurogenic efficacy, these long-term studies were allowed us to
determine the disease modifying effects afforded by the therapeu-
tic regimen. Our group tested three treatment regimens—once
per month, once per week, and every other day (Chen et al., 2011).
Overall, we found that the optimal treatment paradigm with sub-
cutaneous Allo, administered once-per-week for 6-months was
maximally efficacious for both neurogenic and anti-Aβ endpoints
(Importance of regimen discussed in greater detail above). Addi-
tionally, these studies demonstrated that together with the dosing
frequency, the magnitude of pathology at the start of treatment
intervention is critical to the window of therapeutic opportunity
for Allo. Administration of Allo prior to and during the early
stages of AD pathology significantly increased the regenerative
response in brain while additionally reducing burden of pathol-
ogy in an AD mouse model (Chen et al., 2011). In contrast, Allo
treatment initiated at the point of Aβ plaque generation was not
efficacious indicating that Allo targets regenerative and pathology
reducing mechanisms present during the early to mid stages of
the disease (Chen et al., 2011). After intraneuronal Aβ is extracel-
lularly distributed, Allo’s efficacy becomes markedly diminished.
Based on a collective body of preclinical data evaluating dose and
route (Irwin et al., 2011; Brinton, 2013; Irwin and Brinton, 2014),
we have selected the once per week regimen to move forward to
FDA-compliant chronic toxicology studies and early phase clinical
trials.
PARKINSON’S DISEASE
Disease target
Regenerate dopaminergic system of the brain and etiology of
pathology.
Therapeutic response to Allo
Neurogenesis in the substantia nigra, functional improvement
in motor control (Adeosun et al., 2012), modulates dopamine
release (Rouge-Pont et al., 2002).
Dose and treatment regimen
Intermittent exposure: 10 mg/kg once a week for 2 weeks in mice
(Adeosun et al., 2012).
Clinical studies investigating the levels of endogenous Allo in
PD patients demonstrated that in males, the levels of endoge-
nous Allo were decreased both peripherally and in the CNS (di
Michele et al., 2003, 2013). While Allo concentrations in specific
human brain regions affected by PD has not been studied, in
healthy women, the highest Allo levels were observed in the
substantia nigra (SN) and basal hypothalamus (Bixo et al., 1997).
The therapeutic goals for exogenous Allo are the modulation of
dopamine release, restoration of neuroprotection, modulation of
basal GABAergic tone, and neuroregeneration (Luchetti et al.,
2010, 2011; Adeosun et al., 2012; di Michele et al., 2013). As in
AD, the dose and therapeutic regimen must be carefully consid-
ered, as low doses Allo increases dopamine release, but at high
doses decreases release (Rouge-Pont et al., 2002). In preclinical in
vivo studies, once weekly Allo administration has demonstrated
functional improvement (Adeosun et al., 2012).
MULTIPLE SCLEROSIS
Disease target
White matter regeneration in the peripheral and central nervous
systems, reduce inflammation, etiological mechanism of disease,
and prevention of relapse.
Therapeutic response to Allo
Oligogenesis (Garay et al., 2012; Schumacher et al., 2014), neuro-
genesis (Ghoumari et al., 2003; Gago et al., 2004), cytoprotective,
promyelination (Melcangi et al., 1999; Noorbakhsh et al., 2011),
anti-inflammatory (Noorbakhsh et al., 2011), reduced disease
severity (Noorbakhsh et al., 2011), innate immune function mod-
ulator (Noorbakhsh et al., 2014).
Dose and treatment regimen
Continuous exposure: daily IP 10 mg/kg for 28 days in mice
(Melcangi et al., 1999). Intermittent paradigm: 1 mg SC every 4
days for 1 month in rats (Noorbakhsh et al., 2011).
The peripheral nervous system synthesizes steroid hormones,
including progesterone, and possesses the enzymes required to
convert these molecules to neuroactive metabolites, including
Allo (Melcangi et al., 1999). In cases where the endogenous levels
are insufficient, treatment with exogenous Allo could produce
therapeutic benefit (Melcangi et al., 1999). Analyses of endoge-
nous Allo showed that in MS patients, the Allo concentration
in white matter was significantly decreased, demonstrating the
potential for Allo as a potential therapeutic for this as yet unmet,
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clinical need (Noorbakhsh et al., 2011). A number of preclinical
in vivo and in vitro studies have demonstrated the potential for
Allo as a MS therapeutic through its anti-inflammatory effects,
neurogenesis, and induction of myelin production (Melcangi
et al., 1999; Ghoumari et al., 2003; Gago et al., 2004; Noorbakhsh
et al., 2011). Common themes, seen in Allo studies for the disease
states presented above, also apply to its utilization for MS. Efficacy
is limited in late-stage disease, indicating that the system must
retain neurogenic potential for therapeutic effect (Melcangi et al.,
1999). Allo dosage and treatment regimen have been shown to
be critical factors in study design. Positive effects of treatment
were limited in in vitro studies when length of treatment was
less than 24 h (Melcangi et al., 1999). As in AD, more Allo
is not beneficial, and in vitro dose-response curve studies have
demonstrated that the positive proliferative effects of Allo peak
at 10 nM doses, and decrease with increasing doses (Gago et al.,
2004).
NIEMANN-PICK TYPE C
Disease target
Cholesterol trafficking and clearance system of the brain and
etiology of disease.
Therapeutic response to Allo
Increased survival, decreased rate of motor control decline,
increased neuronal survival, decreased cholesterol accumulation
(Griffin et al., 2004), and reduced oxidative stress (Zampieri et al.,
2009).
Dose and treatment regimen
Single dose exposure: 25 mg/kg SC, single injection in mice
(Griffin et al., 2004). Continuous exposure: 0.5–2 mg in drinking
water (ascending dose; lifetime treatment); 250 mg/90 days SC
implant (lifetime treatment) in mice (Griffin et al., 2004).
NPC is a fatal, neurodegenerative, lysosomal storage disorder
that affects cholesterol metabolism due to autosomal recessive
mutations in the NPC1 and LPC2 loci. Allo has been studied for
its therapeutic effect on NPC, which is characterized by defective
trafficking of intracellular cholesterol and lysosomal accumu-
lation of unesterified cholesterol gangliosides and other lipids
leading to neurological deterioration and degenerating motor and
cognitive function. Characterization of the NPC mouse model
suggested dysfunctional steroidogenesis from cholesterol, giving
credence to the indication for Allo (Griffin et al., 2004). In vivo
studies have demonstrated that Allo, administered using continu-
ous exposure paradigms results in improved outcomes, including
survival and a decreased rate of decline of locomotion and motor
coordination (Griffin et al., 2004). In addition to these functional
improvements, histological examination demonstrated increased
cerebellar neuron survival and decreased accumulation of cortical
gangliosides (Griffin et al., 2004). Interestingly, in this disease
state, continuous Allo administration via treated water resulted
in superior survival outcomes vs. a single Allo SC dose. As has
been shown in other disease states treated with Allo, timing of
the single-dose injection is vital. Outcomes are best when Allo
is administered early postnatally as efficacy diminishes and is
quickly lost with advancing disease state (Griffin et al., 2004). In
vitro studies have demonstrated a significant antioxidant function
of Allo, but this remains to be translated to in vivo preclinical
models (Zampieri et al., 2009).
FXTAS AND FRAGILE X SYNDROME
Disease target
Regenerative system of the brain and etiology of disease.
Therapeutic response to Allo
Improved functional electrical impairments in vitro culture of
neurons from a mouse model of the disease (Cao et al., 2012).
Dose and treatment regimen
0.01–1 µM (in vitro) (Cao et al., 2012).
Preclinical studies demonstrate that Allo is efficacious in
neural cells isolated from a fragile X-associated tremor/ataxia
syndrome (FXTAS) mouse model (Cao et al., 2012). This mouse
model has defects in neuronal morphology and migration. FXTAS
related defects occur in basal electrical activity exhibited by
permutation CGG repeat expansion-carrying neurons associated
with a gain-of-function in type-I mGluRs and/or a loss-of-
function in GABAAR signaling. Allo acutely improved the func-
tional impairments as measured by electrical burst firing, in this
preclinical model.
Furthermore, an Allo analog, ganaxolone, formulated in an
oral suspension, given in three divided doses (ClinicalTrials.gov
identifier: NCT01725152) is currently in Phase 2 proof-of-
concept study in children with fragile X syndrome. Fragile X
syndrome is the most common inherited form of cognitive
impairment results from a single-gene disorder associated with
autism. The aim of the study is to assess the safety, tolerability
and efficacy of ganaxolone for treatment of anxiety and attention
deficits in subjects with fragile X syndrome. The clinical trial is
designed to test ganaxolone treatment compared to placebo on
measures of anxiety and attention via several neuropsychological
and psychometric tests.
DIABETIC NEUROPATHY
Disease target
Regenerate peripheral nerve, reduce pain, increase conductivity of
peripheral nerves, and etiological mechanism of disease.
Therapeutic response to Allo
Decreased expression of apoptosis mediators, increased noci-
ception threshold (Afrazi et al., 2014), increased nerve conduc-
tion velocity, and restored intra-epidermal nerve fiber density
(Leonelli et al., 2007).
Dose and treatment regimen
Intermittent exposure in rats: 5 mg or 20 mg/kg, gastric lavage, for
8 weeks (Afrazi et al., 2014); 3.3 mg/kg SC every 4 days for 8 doses;
3.3 mg/kg SC every 2 days for 16 doses (Leonelli et al., 2007).
Diabetic neuropathy is a unifying term for a heterogenous
assembly of symptoms resulting from long-term glucose instabil-
ity. Neuronal damage, dysfunction and apoptosis can present in
patients in a myriad of ways including spontaneous pain, hypoes-
thesia, allodynia and hyperalegsia. Neurosteroid levels have been
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shown to fall in neuropathic pain conditions (Patte-Mensah et al.,
2005; Saredi et al., 2005), validating the assessment of Allo for this
indication. In vivo studies have demonstrated the effect of Allo
on improving nociceptive threshold and decreased expression of
apoptosis mediators (Afrazi et al., 2014). The theme of an optimal
dosage regimen is continued here; Allo demonstrated superior
restoration of nerve conduction velocity and intra-epidermal
nerve fiber density when administered every other day for 30
days vs. every 4 days for 28 days (Leonelli et al., 2007). As in
AD and MS, a higher Allo dose is not beneficial, and an in vitro
dose-response curve study have demonstrated that the positive
cell viability effects of Allo in glucose induced cell toxicity peak
at the 2.5 µM dose, and decrease with increasing doses (Afrazi
et al., 2014).
STATUS EPILEPTICUS
Disease target
Spontaneous seizure activity of the brain.
Therapeutic response to Allo
Dampens epileptic seizure activity and reduce neuroexcitotoxicity
(Rogawski et al., 2013).
Dose and treatment regimen
Immediate and continuous treatment regimen in 6 Hz seizure
model, 1.5 mg/kg Allo IV conferred seizure protection within
1 min after dosing in mice (Rogawski et al., 2013; Zolkowska et al.,
2013).
Most seizures are spontaneously terminated within a short
period of time because of endogenous inhibitory mechanisms
including actions of Allo on GABAARs. However, when seizures
do not stop spontaneously, this results in status epilepticus, a
life-threatening neurological emergency condition. Allo is cur-
rently in clinical trials on emergency basis for certain cases of
status epilepticus (Rogawski et al., 2013). Previously, ganaxolone
was being developed for infantile spasms (Gasior et al., 2000;
Kerrigan et al., 2000; Kaminski et al., 2004). Standard treat-
ment for status epilepticus is administration of benzodiazepines
but in many cases these quickly become ineffective. GABAARs
are in a continuous cycle of insertion into the cell membrane
and internalization (Goodkin et al., 2005). Internalization of
GABAARs occurs through clathrin-dependent endocytosis. This
process is activated by calcium-phospholipid dependent pro-
tein kinase C (Chapell et al., 1998; Filippova et al., 2000) and
brain-derived neurotrophic factor (Jovanovic et al., 2004). Inter-
nalization of the surface GABAARs correlates with a reduced
response to GABA, whereas inhibition of internalization results in
increased amplitude of synaptic GABAAR currents (Kittler et al.,
2000).
The benzodiazepine-binding site within the GABAAR complex
is located within the α-subunit interface with the δ-subunit and
after synaptic receptor internalization, epilepsy patients often
become resistant to therapy. Neurosteroid binding sites are within
the α-subunit or α/β interface and are not reliant on the δ-subunit
composition. Extrasynaptic GABAARs that contain a δ-subunit
rather than a γ-subunit are sensitive Allo molecular targets that
do not have drug resistance complications and improve treatment
of seizures. Recent resurgence of interest in Allo and its analogs
has prompted attention for this important disease application to
dampen epileptic seizure activity and reduce neuroexcitotoxicity
(Rogawski et al., 2013).
TRAUMATIC BRAIN INJURY
Disease target
Glutamate excitotoxicity systems of the brain.
Therapeutic response to Allo
Anti-inflammatory (VanLandingham et al., 2007), neuroprotec-
tive (Sayeed et al., 2009), anti-convulsant (Rogawski et al., 2013).
Dose and treatment regimen
Immediate and continuous exposure. Within 8 h after injury,
a continuous IV Allo regimen for traumatic brain injury (TBI)
is administered during a 4-day treatment period followed by a
1-day dose de-escalation period in humans (ClinicalTrials.gov
identifier: NCT01673828) (Rogawski et al., 2013).
The adult brain has been shown to possess regenerative mech-
anisms after infarct and injury. In rodents, proliferation in the
SVZ, migration of new neurons to peri-infarct site, and survival
of these new neurons has been demonstrated following stroke
and involves the inflammatory cytokines and chemokines systems
to aid recovery (He et al., 2004b; Djebaili et al., 2005). It has
been hypothesized that angiogenesis leads to functional recovery
through its interaction with one or more aspects of tissue repair,
including neurogenesis (Carmichael, 2010). There is currently
no effective treatment available for TBI victims. TBI may induce
coma or a minimally conscious state and may lead to neurobehav-
ioral deficits including cognitive deficits. Long-term consequences
of TBI include increased risk for epileptic seizures, PD, and AD
(Annegers et al., 1998; Mueller et al., 2009; Hutson et al., 2011;
Johnson et al., 2012). A challenge for TBI research is the extent of
heterogeneity of these brain injuries and the delayed secondary
injuries due to increases in intracranial pressure, hypoxia, and
glutamate excitotoxicity (Mueller et al., 2009). A TBI case study
of two patients who recovered after years in a state of minimal
consciousness suggests that brain regeneration and specific axonal
regrowth to improve quality of life is possible even after severe TBI
(Voss et al., 2006).
Allo is currently in clinical trials to assess the safety and efficacy
of Allo in improving neurobehavioral outcome and reducing
mortality in adults with moderate and severe TBI (ClinicalTri-
als.gov identifier: NCT01673828). Within 8 h after injury, a con-
tinuous IV Allo regimen for TBI is administered during a 4-day
treatment period followed by a 1-day dose de-escalation period
(ClinicalTrials.gov identifier: NCT01673828). This continuous
treatment regimen is very different from the regenerative regimen
approach taken for Allo in chronic neurodegenerative diseases.
This regimen takes advantage of the anticonvulsant mechanisms
of Allo action to limit acute brain excitoxicity (Figure 3). Allo and
its precursor progesterone acutely reduce inflammatory cytokines
after brain injury (He et al., 2004a,b; Djebaili et al., 2005).
Allo has been shown to upregulate CD55, a cell surface protein
that inhibits convertase enzymes to reduce neuroinflammation
(VanLandingham et al., 2007). Another possible mechanism of
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Allo-induced neuroprotection is a direct inhibition of the mito-
chondrial permeability transition pore. By this mechanism, Allo
was shown to inhibit calcium ion-triggered swelling in function-
ally intact rat liver and brain mitochondria (Sayeed et al., 2009).
INTEGRATION OF TRANSLATIONAL DETERMINANTS INTO
THE CLINICAL TRIAL DESIGN FOR AD AND OTHER
DISORDERS MATTERS
Fundamental translational determinants of success are well-
defined mechanisms of action, dose-response relationships, and
optimal therapeutic regimen. Mechanistically, a key to therapeutic
success is an understanding of the intended activated pathways as
well as those that are unintentionally activated. This is not always
possible but always beneficial. A well-defined understanding of
dose-response relationship includes doses that are sub-optimal
and which induce toxicity or off-target effects. In the case of
Allo, the dose-response relationship indicates that a sedative dose
suppresses regeneration and thus establishes the maximally toler-
ated dose. Further, daily exposure to Allo at a non-sedative dose
also suppresses regeneration. The dose and exposure relationships
provide critical information for clinical trial design as well as
providing key insights into the regenerative system of the brain.
The maximally tolerated dose will depend on the neurological
condition, intended mechanism of action, and the therapeutic
goals (Figure 3). For example, a low dose of Allo with inter-
mittent exposure is optimal for activating regenerative responses.
Whereas, TBI and status epilepticus require emergency suppres-
sion of glutamate excitotoxicity necessitating a high dose of Allo
administered by continuous infusion.
Clinical trial design is inextricably linked to therapeutic suc-
cess. Recently, the Food and Drug Administration (FDA) released
a draft guidance document for developing drugs for early-stage
AD trials (Food Drug Administration, Center for Drugs Evalua-
tion Research, 2013) that aimed to improve the design of future
AD clinical studies. The FDA guidance emphasized the use of
the Clinical Dementia Rating Scale as a primary clinical scale to
accelerate development of AD drugs. In addition to these cog-
nitive and functional measures, exploratory outcomes for early
stage AD trials can be incorporated into the design as secondary
outcomes (Schneider, 2014). Exploratory outcomes are useful
to detect responsiveness to new therapies such as correlations
between neuroregenerative indicators and improvement in brain
activity (Mullard, 2012, 2013; Schneider, 2014).
Adaptive clinical trials are designed to conduct interim anal-
yses that are prospectively planned (Food Drug Administration,
Center for Drugs Evaluation Research, 2010). An adaptive design
affords the opportunity to modify one or more aspects of the
study based on a hypothesis-driven analysis of the data. The
benefit of an adaptive design is the opportunity to learn about the
impact of the therapeutic agent early in the course of the study and
to make course corrections earlier rather than later. These analyses
would be hypothesis driven and based on predictive biomarkers of
efficacy.
What defines biomarkers that align with stage of disease and
are predictive of therapeutic efficacy? Potential biomarkers of effi-
cacy relevant to regeneration could be evident as either decreased
rate of degeneration or an increased rate of structural recovery.
Thus we reasoned that if Allo was promoting regeneration in the
brain, that regeneration could be evident in MRI-based measures
of hippocampal volume, diffusion tensor imaging of white matter,
and resting default mode network (Brinton, 2013). If structural
integrity is related to function, then one would predict a delay in
severity of dementia and or recovery of cognitive function. We
anticipate, based on the temporal requirements for regeneration
in the context of a degenerated brain, that the regeneration of the
neural circuitry that underlies the resting default mode network
has the greatest probability of being the first imaging biomarker
to exhibit change over time.
Clinical trials of potential disease modifying agents require
the ability to characterize a well-defined study cohort (Sperling
et al., 2011a). The National Institutes of Aging and the Alzheimer’s
Association published disease-staging criteria that describe the
clinical stages of AD (Albert et al., 2011). For clinical development
of Allo, initial targeted populations are those with mild cognitive
impairment or early AD (Brinton, 2013). These populations were
targeted based on preclinical analyses indicating that Allo exerted
a regenerative response in transgenic AD mice with burden of
pathology relevant to early stage AD. These animals exhibited cog-
nitive and neurogenic deficits that were reversed by Allo (Brinton,
2013). At later stages of the disease, the regenerative capacity was
depleted and thus not appropriate for a therapeutic that promotes
endogenous regeneration (Brinton, 2013).
Collectively, it is clear that clinical trial testing of Allo across
multiple neurodegenerative diseases will require translational
research specific to the disease, dosing to the intended target,
treatment regimen specific to the respective system, and study
population specific to stage of disease.
CONCLUDING REMARKS
The goal of this review was to integrate existing knowledge rele-
vant to translational development of Allo as a therapeutic agent
for multiple neurological disorders. There are multiple leverage
points across programs of therapeutic development that could
significantly accelerate time-to-clinical trial of Allo in each of
these conditions (Figure 5). Allo activates multiple systems in
multiple cell types in multiple anatomical regions with therapeu-
tic implications for multiple diseases. Each neurological disease
has specific Allo dose and therapeutic regimen requirements that
must be tested preclinically and must be carefully translated to
clinical study design. Leverage points—such as preclinical efficacy
data, preclinical toxicology data, regulatory knowledge, access
to clinical-grade material, and access to clinical data matter to
development of expedited timelines to utilize Allo across these
disorders (Figure 5). For Allo to reach its potential as a ther-
apeutic option, the formulation, dosing regimen, and route of
administration are critical determinants of success. Considera-
tions of gender, genetics, age, and progression of disease for both
preclinical translational analyses and clinical trials are critical
(Figure 4).
The therapeutic potential of Allo for multiple neurological
diseases is increasingly appreciated. Different etiologies, different
courses of disease progression, different mechanisms involved
in the disease, will impact the therapeutic efficacy of Allo. In
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FIGURE 5 | Development of allopregnanolone for neurological disorders.
Leverage points along the standard timeline of 12 years and up to 20+ years
as drug development proceeds to the marketing approval target. By sharing
resources and information, it is plausible to accelerate therapeutic
development timelines to 8 years or less, completing clinical trials more
rapidly for unmet medical needs.
turn, it is essential that translational research target each of the
neurological disorders and take into consideration the similarities
and differences in molecular targets and etiology of disease. To
suppress neuronal excitability in TBI or epilepsy, it makes sense to
inhibit excitability as early as possible following injury. In other
cases, maximizing GABAergic suppression of the brain in the
absence of glutamate excitotoxicity is unlikely to have therapeutic
benefit and could induce harm. Pragmatically, this translates into
dosage levels and treatment regimens tailored to the neurological
disorder and therapeutic goals in the context of the relevant
systems biology.
We have reviewed herein compelling preclinical discovery
outcomes that strongly suggest the therapeutic potential of Allo.
Translation of Allo to clinical studies requires systematic establish-
ment of the optimal target engagement, dose, treatment regimen,
duration of treatment, and safety. What remains is to leverage
the discovery science into the path of translation. Fortunately,
and remarkably, there are multiple opportunities to leverage
existing translational knowledge and to systematically apply that
knowledge in disease relevant models to accelerate determination
of Allo efficacy across multiple disease states.
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